Phase 2a data for Newron's schizophrenia drug evenamide due in March should help the company sign a development partner later this year, says CEO.

KeyBioscience has turned to Enteris BioPharma for help creating oral formulations of a metabolic peptide.

As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…

Pfizer has become the latest Big Pharma company to join a consortium that matches drugmakers to researchers in Cambridge, U.K.

The J.P. Morgan event is known as the event for biotech and the investor community and, although typically aimed at generalists, bio journalists are always on…

Pierre Fabre has struck a deal to develop dermatological formulations of Piqur Therapeutics’ PI3K/mTOR inhibitor PQR309.

NeuroVive Pharmaceutical has entered into a research collaboration with Karolinska Institutet.

AbbVie has unveiled a clutch of pacts in fields including immuno-oncology and genomics.

It’s the time of year for editors to look ahead and attempt to predict, based on the patterns of the past 12 months, what the next trip around the sun will…